ArticleVeterinary research2026
Localized adaptive evolution in VP1 drives antigenic divergence of feline calicivirus despite high sequence conservation.
Article in Veterinary research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Feline calicivirus (FCV) evolves rapidly under immune pressure, yet the genetic basis of antigenic escape remains poorly understood, particularly when sequence divergence is limited. We isolated 13 FCV strains from cats in Jilin Province, China, between 2018 and 2024, and characterized their genetic and antigenic properties. Phylogenetic analysis of the major capsid protein VP1 revealed the co-circulation of multiple lineages, including isolates clustering within clades associated with virulent systemic disease (VSD) and grouping with strains previously identified in dogs. Cross-neutralization assays demonstrated that the vaccine-induced antiserum neutralized most isolates but exhibited markedly reduced neutralizing activity against JL1907 and JL2103, both of which were isolated from vaccinated cats. Notably, despite sharing 91.9% amino acid identity in VP1, JL2103 and JL2104 exhibited highly asymmetric cross-neutralization: Antiserum raised against JL2103 failed to neutralize JL2104, whereas antiserum raised against JL2104 potently neutralized JL2103. Comparative sequence analysis identified nonsynonymous substitutions concentrated in E region (the hypervariable region of VP1), particularly within predicted B cell epitopes and residues proximal to the feline junctional adhesion molecule A (fJAM-A) binding interface. Our findings indicate that minor amino acid substitutions at critical antigenic sites are sufficient to disrupt cross-neutralization, even among closely related FCV strains, thereby providing a mechanistic basis for antigenic escape under constrained genetic divergence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.